Abstract
Objective:
The authors compared low-dose sustained-release bupropion with placebo for sexual dysfunction induced by selective serotonin reuptake inhibitors (SSRIs).
Method:
Thirty adults who had received SSRIs for at least 6 weeks, who were euthymic, and who had sexual dysfunction as determined by a total score greater than 19 out of a possible 30 on the Arizona Sexual Experience Scale were randomly assigned to receive either 150 mg/day of sustained-release bupropion or placebo at 6:00 p.m. for 3 weeks.
Results:
There were no significant differences between the sustained-release bupropion and placebo groups as measured by change in Arizona Sexual Experiences Scale or Hamilton Depression Rating Scale scores or side effects.
Conclusions:
Future studies should compare higher doses of bupropion for treating sexual dysfunction and should include a greater number of subjects.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Antidepressive Agents, Second-Generation / administration & dosage*
-
Antidepressive Agents, Second-Generation / pharmacology
-
Antidepressive Agents, Second-Generation / therapeutic use
-
Bupropion / administration & dosage*
-
Bupropion / pharmacology
-
Bupropion / therapeutic use
-
Delayed-Action Preparations
-
Double-Blind Method
-
Drug Therapy, Combination
-
Erectile Dysfunction / chemically induced
-
Erectile Dysfunction / drug therapy
-
Female
-
Humans
-
Libido / drug effects
-
Male
-
Penile Erection / drug effects
-
Selective Serotonin Reuptake Inhibitors / adverse effects*
-
Selective Serotonin Reuptake Inhibitors / therapeutic use*
-
Sexual Dysfunctions, Psychological / chemically induced*
-
Sexual Dysfunctions, Psychological / drug therapy*
-
Treatment Outcome
-
Vagina / drug effects
-
Vagina / metabolism
Substances
-
Antidepressive Agents, Second-Generation
-
Delayed-Action Preparations
-
Serotonin Uptake Inhibitors
-
Bupropion